Previous 10 | Next 10 |
SEATTLE, March 26, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the Institutional Review Board (IRB) has ap...
Just like 2016, 2020 presidential candidates are likely to make healthcare costs a top priority. How to deal with rising costs remains to be seen, but the good news is technology is already helping in some key settings. Telehealth and remote patient monitoring have seen increased tra...
Atossa Genetics Inc. ( ATOS ) had a wild week last week after announcing that its proprietary oral Endoxifen was granted "Expanded Access" by the FDA for Post-Mastectomy Treatment for a U.S. Breast Cancer Patient. Third time was apparently a charm since the company announced it was origina...
Gainers: Dermira (NASDAQ: DERM ) +85% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +48% . Atossa Genetics (NASDAQ: ATOS ) +35% . American Midstream Partners (NYSE: AMID ) +28% . Aclaris Therapeutics (NASDAQ: ACRS ) +21% . Innovate Biopharmaceuticals (NASDAQ: INNT ) +20% . Profess...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +108% on positive PB2452 data . More news on: PhaseBio Pharmaceuticals, Inc., Dermira, Inc., Leap Therapeutics, Inc., Stocks on the move, Read more ...
SEATTLE, March 18, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that on March 14 and 15, 2019, it received appro...
Data by YCharts Data by YCharts Headquartered in Seattle, Wash., Atossa Genetics ( ATOS ) reported significant news on 2/7/19 and again on 3/14/19 that the FDA had issued a "Safe To Proceed" letter under the FDA's Expanded Access program granting approval for the use of one of the comp...
Gainers: Soleno Therapeutics (NASDAQ: SLNO ) +210% . Achieve Life Sciences (NASDAQ: ACHV ) +33% . Catasys (NASDAQ: CATS ) +26% . Prana Biotechnology (NASDAQ: PRAN ) +24% . Avid Technology (NASDAQ: AVID ) +23% . Magenta Therapeutics (NASDAQ: MGTA ) +22% . Leap Therapeutics (NASD...
Kopin (NASDAQ: KOPN ) -24% on secondary offering . More news on: Kopin Corporation, PHI, Inc., Yield10 Bioscience, Inc., Stocks on the move, Read more ...
Shares of Atossa Genetics (NASDAQ: ATOS ) surged significantly on Thursday (March 14) after the US Food and Drug Administration (FDA) granted an approved-expanded access program for the company’s oral version of Endoxifen. According to the press release, the agency gave Atossa Genet...
News, Short Squeeze, Breakout and More Instantly...
Atossa Therapeutics Inc. Company Name:
ATOS Stock Symbol:
NASDAQ Market:
Atossa Therapeutics Inc. Website:
SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study has fully...